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journal homepage: http: / /www.pediatr -neonatol .comLETTER TO THE EDITORThe Pandora’s Box of Neonatal AnalgesiaWe thank Dr Allegaert and colleagues for their interest in our
report.1,2 We share with them the same trust in the great
potentiality of remifentanil anesthesia in preterm babies.
However, they pose a very challenging question: does the
pharmacokinetic approach actually correspond to the best
pharmacodynamic result? This question, which refers to the
practice of administering anesthesia to preterm babies, al-
lows us to open a “Pandora’s box” full of unknown issues.
Tolerance, hyperalgesia, and withdrawaldreal risks in
the use of opioidsdare produced by mechanisms that
remain poorly understood even in adults, suggesting that a
receptorial deregulation in pain pathways could be
responsible. Therefore, in our clinical practice, we are
obliged to extrapolate the data, applying unclear knowl-
edge to an as yet extremely immature physiology.
Wesuppose, and someevidenceappears in the literature,3
thatprolongeduseof remifentanilmay lead to tolerance, and
high doses may also induce hyperalgesia in preterms. Rota-
tionwith other opioids in the postoperative period is not easy
and burdened by several problems. Long-acting opioids, such
as morphine and fentanyl, have a too variable effect in pre-
mature babies that can be increased by illness in which he-
patic blood flow and intra-abdominal pressure are modified.
In these patients, the risk of underdosing or of a thera-
peutic gap is high, and long-term effects are probably worse
than those induced by overdosing. It seems well established,
in fact, that painful experiences in the early stage of life can
affect the anatomical neurodevelopment, involving future
behavioral and socialeemotional outcome.4 Remifentanil
appears to be the more appropriate choice because, as per
reasons mentioned above, the more predictable and easy
drug should be used.
We agree with our colleagues about the need for focused
studies on controversies regarding pain assessment in neo-
nates and preventive drugs. Incidentally, we are not
allowed to use such drugs as ketamine that could help in
the prevention of pain in premature babies less than 32
weeks because of the well-known possibility of inducing
apoptosis in the central nervous system of extremely low
birth weight infants.51875-9572/$36 Copyright ª 2013, Taiwan Pediatric Association. Publish
http://dx.doi.org/10.1016/j.pedneo.2013.03.010In view of the above awaiting future insights, we remain
convinced about our choice to use remifentanil as the sole
opioid during and after major surgery in preterm
babies, based on the possibility of an easy titration and
contained risks, and ensuring hemodynamic stability and
neuroprotection.
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